New equity financing would provide the Company sufficient financial visibility to execute its strategic plan and achieve profitability
The future exercise of share subscription warrants (BSA) issued as part of the transaction could bring the total amount of the financing to over €11m
Paris and Boston, October 21, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announced it has secured firm subscription commitments for an amount exceeding €5 million, corresponding to the minimum target set by its draft safeguard plan (the “Safeguard Plan“).
This crucial step comes ahead of the hearing scheduled for October 27 at the Paris Commercial Court (the “Court“), which will rule on the approval of the Safeguard Plan.
The Company is continuing discussions with several other family offices and entrepreneurs to maximize the amount of commitments prior to the launch of the transaction.
The capital increase, which will be carried out via a private placement of shares with attached warrants (ABSA) after the Safeguard Plan is approved by the Court, will provide the Company with the necessary financial resources to execute its strategic roadmap and achieve its profitability target by 2027.
The terms of the transaction, notably the subscription price and the characteristics of the warrants (BSA) issued to new investors and existing shareholders, remain unchanged and are described in the press release dated October 8, 2025.
This is a new important milestone which arrives when the Company registers a very positive commercial momentum, marked by a notable commercial acceleration in the United States and a significant improvement in its financial results. This progress confirms the relevance of the strategy being implemented and the Company’s ability to successfully execute its plan.
Sacha Loiseau, Chairman, CEO and founder of Mauna Kea Technologies, concluded: “Securing these firm financing commitments is a decisive step in our turnaround plan. Moreover, it reflects investors’ confidence in the new chapter opening for Mauna Kea while allowing us to anticipate a favorable outcome of the safeguard procedure. I am particularly pleased to have the support of renowned entrepreneurs and investors from the healthcare sector across several geographies, who recognize the value creation inflection point that I am convinced lies ahead of us. We are approaching this new phase with renewed discipline and the determination to rapidly achieve profitability, expand clinical adoption of Cellvizio, and rebuild value for all stakeholders.”
Indicative Timeline
- October 27, 2025: Hearing of the Paris Commercial Court on the safeguard plan
- First half of November 2025: Court’s decision and setting of the ABSA Issue Price
- Within 2 trading days following the setting of the Issue Price: Settlement and delivery of the new ABSA
